Tocainide

Summary

Tocainide (CHEMBL1762) is an approved small-molecule local anaesthetic (ATC C01BB03); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C01BB03
• Indications: 1 condition
• Chemistry: 192.26 Da · C11H16N2O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1762
Name	Tocainide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	38945
ChEBI	CHEBI:9611
ATC	C01BB03
Molecular formula	C11H16N2O
Molecular weight	192.26
InChIKey	BUJAGSGYPOAWEI-UHFFFAOYSA-N

SMILES: CC1=C(C(=CC=C1)C)NC(=O)C(C)N

IUPAC name: 2-amino-N-(2,6-dimethylphenyl)propanamide

ChEBI definition: A monocarboxylic acid amide in which 2,6-dimethylphenylaniline and isobutyric acid have combined to form the amide bond; used as a local anaesthetic.

Pharmacological roles (ChEBI): local anaesthetic, anti-arrhythmia drug, sodium channel blocker.

Also known as: Tocainida, Tocainide, W-36095, SID90341559, TOCAINIDE, rac-Tocainide, tocainide, C0164881, TOCAINIDE HYDROCHLORIDE

Parent form; salt/anhydrous children: CHEMBL1200773

Patent coverage: 1,686 distinct patent families (5,657 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Adenosine receptor A3.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).